Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 5, 2023Viele Menschen mit chronischen Schmerzen sind laut Umfrage bereits in jungen Jahren betroffen und Frauen fühlen sich mit ihren Schmerzen vom Umfeld wenig verstanden.
Düsseldorf – 5. September 2023 – Boston Scientific veröffentlichte heute Ergebnisse einer repräsentativen Befragung von 1.000 Menschen mit chronischen Schmerzen, laut denen dieses Leiden in...
-
Sep 5, 2023Research conducted in the United Kingdom for pain awareness month points to a gender difference in the experience of chronic pain, pursuing pain relief and the feeling of being understood
HEMEL HEMPSTEAD, United Kingdom – 5 Sept. 2023 – Boston Scientific (NYSE: BSX) today revealed survey results of 2,000 people living with chronic pain in the United Kingdom (UK) that unveiled...
-
May 18, 2023Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel
Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel CLONMEL, IRELAND (19 May 2023) - Boston Scientific Corporation (NYSE: BSX) will today announce an €80 million...
-
Nov 29, 2022
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...
-
Nov 8, 2022El algoritmo de doble etapa detecta y verifica posibles arritmias cardíacas para ayudar a aumentar la eficiencia clínica
MADRID, 8 de noviembre de 2022 - Boston Scientific ha anunciado hoy, a la comunidad médico-científica especializada, el lanzamiento en Europa del Sistema de Monitor Cardíaco Insertable (MCI)...
-
Nov 8, 2022Zweistufiger Algorithmus erkennt und überprüft potenzielle Herzrhythmusstörungen, um klinische Wirksamkeit zu steigern
Düsseldorf, 8. November 2022 – Die Boston Scientific Corporation (NYSE: BSX) gab heute die Markteinführung des LUX-Dx Insertable Cardiac Monitor (ICM) Systems in Europa bekannt. Das...
-
Nov 8, 2022Algoritmo a doppia fase per verificare potenziali aritmie cardiache
Milano, 8 novembre 2022 - Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi l’introduzione in Europa del nuovo monitor cardiaco inseribile LUX-Dx™ (ICM), un dispositivo diagnostico...
-
Nov 8, 2022Dual-stage algorithm detects and verifies potential heart arrhythmias to help increase clinical efficiency
LONDON, November 8, 2022 – Boston Scientific Corporation (NYSE: BSX) today announced the European launch of the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a long-term diagnostic device...
-
Jun 21, 2022
Ripristinare funzioni vitali e qualità di vita dopo l’asportazione di un tumore alla prostata: le opzioni terapeutiche risolutive e sostenibili per l’incontinenza urinaria maschile Milano, 21...
-
Apr 14, 2022Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years
BOSTON SCIENTIFIC ANNOUNCES €100M INVESTMENT IN GALWAY CAMPUS Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years GALWAY, IRELAND (14 April...
-
Apr 4, 2022More UK patients with Benign Prostatic Enlargement (BPE) should now have improved access to these treatments thanks to inclusion in medtech funding pathway
HEMEL HEMPSTEAD, UK., Mon 4 April, 2022– Boston Scientific Corporation (NYSE: BSX) is pleased to announce the inclusion of two innovative devices in this year’s NHS MedTech Funding Mandate...
-
Feb 15, 2022
MARLBOROUGH, Mass., 15. Februar 2022– Boston Scientific Corporation (NYSE: BSX) hat heute den Abschluss seiner Übernahme von Baylis Medical Company Inc. bekannt gegeben, einem Unternehmen, das...
-
Feb 15, 2022
MARLBOROUGH, Mass., February 15, 2022– Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced...
-
Dec 8, 2021Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 5, 2021Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism
Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
-
Sep 29, 2021Investment earmarked for new technology capabilities and jobs growth
CORK (29 September 2021) – Boston Scientific Corporation (NYSE: BSX) today announced a €30 million investment in its Cork facility to accelerate the development and manufacturing of...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
MARLBOROUGH, Mass. (September 20, 2021) – Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...
-
Sep 2, 2021Terapia sin parestesias de acción rápida clínicamente probada que demuestra un alivio del dolor importante y sostenido en cuestión de minutos
MARLBOROUGH, Mass., 2 de septiembre, 2021- Boston Scientific (NYSE: BSX) anunció hoy el lanzamiento en Europa de la terapia FAST para sus sistemas de estimulación de la médula espinal (SCS)...
-
Sep 2, 2021Fast-Acting Sub-perception Therapy (FAST) clinically proven to demonstrate significant and sustained pain relief within minutes
MARLBOROUGH, Mass., September 2, 2021 – Boston Scientific (NYSE: BSX) today announced the European launch of FAST Therapy for its WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems. The new...
-
Sep 2, 2021Schnell wirkende, klinisch erprobte Sub-Wahrnehmungstherapie, die eine deutliche und dauerhafte Schmerzlinderung innerhalb von Minuten bewirkt
MARLBOROUGH, Mass., 2. September 2021 – Boston Scientific (NYSE: BSX) verkündete heute die Markteinführung von FAST für seine WaveWriter Alpha Rückenmarkstimulations-Systeme (SCS-Systeme) in...
-
Aug 29, 2021
MARLBOROUGH, Mass., DATE, 2021– Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops...
-
Aug 4, 2021Boston Scientific startet randomisierte, kontrollierte Studie für das endovaskuläre System EkoSonic©Studie vergleicht erstmals interventionelle Therapie in Kombination mit Antikoagulation mit Antikoagulation allein zur Behandlung von Lungenembolie
MARLBOROUGH, Mass. (04. August 2021) - Die Boston Scientific Corporation (NYSE: BSX) hat mit der Rekrutierung für die klinische Studie HI-PEITHO begonnen, eine gemeinschaftliche Forschungsstudie...